Sep 2026
Chimeric IL-15 as a next-generation immunotherapeutic: preclinical assessment of efficacy and safety.
It is demonstrated that chimeric IL-15 induces robust antitumor immunity with improved pharmacokinetics and a favourable safety profile, supporting its further preclinical development as a next-generation cancer immunotherapeutic.
Himali Patel, M. Ahuja, Keyur Shah et al.
· International Immunopharmaco... · 0 citations